BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Dec 12, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

PEG-SN38: Phase II data

An open-label, U.S. Phase II trial in 164 patients with metastatic breast cancer showed that once-weekly IV PEG-SN38 for 3 weeks of a 4-week cycle led to an ORR of 21% in patients previously treated with an anthracycline and taxane (n=81) and 11% in patients previously treated with an anthracycline, taxane and capecitabine (n=83). The median...

Read the full 258 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >